The U.S. FDA has issued a safety warning for popular diabetes and weight-loss medications, including Ozempic and Mounjaro, over a potential risk of rare but permanent vision loss.
The U.S. FDA has issued a safety warning for popular diabetes and weight-loss medications, including Ozempic and Mounjaro, over a potential risk of rare but permanent vision loss.
The condition, known as NAION, occurs when blood flow to the optic nerve is reduced, potentially causing sudden, painless vision loss in one eye. After reviewing 126 clinical trials, the FDA required updated safety warnings, although a direct causal link has not been conclusively established.